Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused…
About Us
We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.
Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.
Our Core Values: “RAPID”
Investor Relations
Chembio is a leading point of care diagnostics company focused on detecting and diagnosing infectious diseases.
Our patented DPP® technology platform uses a small drop of blood from the fingertip and provides high-quality, cost-effective results in 15-20 minutes. Our products are sold globally, directly and through distributors, to hospitals, clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
